Interview with the President and CEO: Verastem, Inc. (NASDAQ:VSTM)
Robert Forrester, LL.B., is President and Chief Executive Officer of Verastem, Inc. Mr. Forrester has 18 years of experience as the CEO, COO or CFO of both private and public life science companies with Verastem Oncology; Forma Therapeutics; CombinatoRx (NASDAQ:CRXX), now ZLCS; and Coley (NASDAQ:COLY), which was acquired by Pfizer. Mr. Forrester was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Mr. Forrester worked for the investment banks BZW — now Barclays Capital — and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Mr. Forrester started his career as a lawyer with Clifford Chance in London and Singapore. Mr. Forrester has completed over $12 billion of transactions and holds a LL.B. from Bristol University. Profile
Word count: 2,867
TWST: Would you provide a summary of your pipeline?
Mr. Forrester: We have a pipeline that is focused around novel drug candidates that target